TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
54.34
-0.93 (-1.68%)
At close: Oct 13, 2026, 4:00 PM EDT
54.10
-0.24 (-0.44%)
After-hours: Oct 13, 2026, 7:30 PM EDT
TG Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, TG Therapeutics stock has a consensus rating of "Buy" and an average price target of $69.71. The average 1-year stock price forecast is 28.28% higher than the current stock price, while the lowest is $21 (-61.35%) and the highest is $86 (+58.26%).
Price Target: $69.71 (+28.28%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for TG Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $78 | Buy | Maintains | $78 | +43.54% | Sep 21, 2026 |
| B. Riley Securities | B. Riley Securities | Buy Maintains $86 | Buy | Maintains | $86 | +58.26% | Sep 2, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $65 → $72 | Buy | Maintains | $65 → $72 | +32.50% | Aug 11, 2026 |
| Bank of America Securities | Bank of America Securities | Sell Reiterates $20 → $21 | Sell | Reiterates | $20 → $21 | -61.35% | Aug 5, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $75 | Buy | Maintains | $75 | +38.02% | Aug 4, 2026 |
Financial Forecast
Revenue This Year
960.26M
from 616.29M
Increased by 55.81%
Revenue Next Year
1.32B
from 960.26M
Increased by 37.36%
EPS This Year
0.95
from 2.77
Decreased by -65.70%
EPS Next Year
2.71
from 0.95
Increased by 185.05%
EPS and Forward PE are based on non-GAAP adjusted numbers.